Möchten Sie immer auf dem neuesten Stand bleiben?

Uppsala, Sweden, 20 April, 2016 OssDsign AB, a Swedish designer, manufacturer and distributor of next generation implants for cranial and facial repair, today announced the appointment of Simon...

Uppsala, Sweden, 20 April, 2016 OssDsign AB tillkännager idag att Simon Cartmell valts till ny styrelseordförande i bolaget. Som erfaren entreprenör med mångårig erfarenhet av life science innehar...

Årsredovisningen finns nu tillgänglig på www.karolinskadevelopment.com.   För ytterligare information, vänligen kontakta: Jim Van heusden, VD, Karolinska Development AB Tel: +46 72 858...

The report is now available to download at www.karolinskadevelopment.com     For further information, please contact: Jim Van heusden, CEO, Karolinska Development AB Phone: +46 72...

The new funds will be used by Umecrine Cognition to conduct a Phase I (first in human) clinical trial with the company’s oral drug candidate GR3027 in 58 healthy volunteers to assess safety,...

Aprea kommer att använda kapitaltillskottet till klinisk utveckling av sin läkemedelskandidat APR-246, ett first in class anti-cancerläkemedel som riktas mot och återaktiverar...

The new funds will be used by Aprea to advance the clinical development of its lead cancer program, APR-246, a first-in-class anti-cancer compound that targets and re-activates the tumor suppressor...

Jim Van heusden, CEO of Karolinska Development, said: “Today´s announcement is obviously very disappointing news for patients with acute myeloid leukemia given the great need for improved treatment...

Jim Van heusden, VD i Karolinska Development: Det vi annonserat idag är verkligen en besvikelse för patienter med akut myeloisk leukemi med tanke på det stora behovet av förbättrade...

Jim Van heusden, CEO, comments: “During the course of 2015 we have made significant progress in executing our new strategy which is designed to transform Karolinska Development into a successful...